Neuland Laboratories Quarterly Results for Trading Insights
In Mar 2026, Neuland Laboratories (NEULANDLAB) reported revenue ₹789 Cr and net profit ₹213 Cr — revenue +134.8% YoY. For annual financials, live price and key ratios, visit Neuland Laboratories stock price NSE.
NEULANDLAB Quarterly Results — Revenue, Profit & EPS Highlights
Neuland Laboratories latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Analyse NEULANDLAB FII DII holdings to track promoter, FII and institutional holdings.
- Revenue of ₹789 Cr in Mar 2026 (+21.4% vs Jun 2026, +134.8% vs Mar 2025)
- Net Profit of ₹213 Cr in Mar 2026 (+43.9% vs Jun 2026, +660.7% vs Mar 2025)
- EBITDA of ₹320 Cr in Mar 2026 (+38.5% vs Jun 2026)
- Operating Margin of 40.0% in Mar 2026 (+5.0pp vs Jun 2026)
- Earnings Per Share of ₹165.76 in Mar 2026 (+44.0% vs Jun 2026)
Neuland Laboratories Quarterly Results — Revenue, EBITDA, Net Profit & EPS
NEULANDLAB quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | Jun 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 789 | 650 | 516 | 336 | 301 | 21.4% | 134.8% |
| Net Profit (₹ Cr) | 213 | 148 | 97 | 28 | 14 | - | - |
| EBITDA (₹ Cr) | 320 | 231 | 157 | 59 | 42 | - | - |
| EPS (₹) | 165.76 | 115.10 | 75.49 | 21.67 | 10.83 | - | - |
| Operating Margin (%) | 40.0% | 35.0% | 30.0% | 16.0% | 12.0% | - | - |
NEULANDLAB Share Price Trend — 1-Year Movement Across Quarterly Results
Neuland Laboratories 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. View NEULANDLAB price range for the annual high/low range and current price position.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
NEULANDLAB vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Neuland Laboratories latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹441,477.63 Cr | 1837.3 | 15,018 | 2,710 | -5.6% | - | 18.0% | 162.6 |
|
Divis Laboratories
Mar 2026 |
₹247,469.81 Cr | 9375.0 | 2,986 | 751 | -5.0% | - | 25.2% | 331.2 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4840.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 420.5 |
|
Cipla
Mar 2026 |
₹112,654.03 Cr | 1394.5 | 6,612 | 543 | -9.3% | - | 8.2% | 203.0 |
|
Zydus Life Science
Mar 2026 |
₹112,607.65 Cr | 1160.0 | 7,569 | 1,341 | -4.3% | - | 17.7% | 91.7 |
All amounts in ₹ Crores